Controversies and role of HPV16 in recurrent/metastatic squamous cell cancers of the head and neck

Ann Oncol. 2014 Aug;25(8):1667-8. doi: 10.1093/annonc/mdu194. Epub 2014 May 29.

Authors

K Misiukiewicz¹, M Bonomi², E Demicco³, M Posner⁴

Affiliations

¹ Department of Medicine, Division of Hematology and Medical Oncology, The Tisch Cancer Institute at Mount Sinai Hospital, New York krzysztof.misiukiewicz@mssm.edu.
² Department of Medicine, Division of Hematology and Medical Oncology, Wake Forest Baptist Medical Center, Winston-Salem.
³ Department of Pathology, Mount Sinai Hospital, New York, USA.
⁴ Department of Medicine, Division of Hematology and Medical Oncology, The Tisch Cancer Institute at Mount Sinai Hospital, New York.

PMID: 24875798
DOI: 10.1093/annonc/mdu194

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Monoclonal / therapeutic use
Antibodies, Monoclonal, Humanized / therapeutic use
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Carcinoma, Squamous Cell / diagnosis
Carcinoma, Squamous Cell / drug therapy
Carcinoma, Squamous Cell / pathology*
Carcinoma, Squamous Cell / virology*
Cetuximab
Dissent and Disputes
Head and Neck Neoplasms / diagnosis
Head and Neck Neoplasms / drug therapy
Head and Neck Neoplasms / pathology*
Head and Neck Neoplasms / virology*
Human papillomavirus 16 / physiology*
Humans
Neoplasm Metastasis
Panitumumab
Papillomavirus Infections / complications*
Prognosis
Recurrence
Squamous Cell Carcinoma of Head and Neck

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Panitumumab
Cetuximab